This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Goodnick, P. J. Articles by Goldstein, B. J. Search for Related Content PubMed PubMed Citation Articles by Goodnick, P. J. Articles by Goldstein, B. J. Social Bookmarking                         What's this?

Selective serotonin reuptake inhibitors in affective disorders -II. Efficacy and quality of life

Department of Psychiatry and Behavioral Sciences

Burton J. Goldstein

Department of Psychiatry and Behavioral Sciences and Department of Molecular and Cellular Pharmacology, Health Services Research Center, University of Miami School of Medicine, Florida, USA.

Since their introduction, the selective serotonin reuptake inhibitors (SSRIs) have become one of the most widely used classes of medication in psychiatry. Their popularity is based on apparent efficacy over a wide range of disorders and a favorable side-effect profile. However, as with any psychotropic medication, considerable data are required to define where a drug works and where it does not. There is now a wealth of evidence demonstrating that SSRIs may differ in their efficacy profiles in certain depressive symptoms, in different subtypes of depression, with respect to their ability to maintain efficacy over time, on broader outcomes such as quality of life, and in the consistency of the usually effective minimum therapeutic dose across the age spectrum and across indications. Although this review includes data on all SSRIs, it focuses on fluoxetine and sertraline, which in addition to being the most widely used SSRIs are also the most widely studied. The relative quantity and quality of data on these two SSRIs means that it is possible to make relatively firm inferences regarding their differential effects on affective symptoms and quality of life.

Key Words: acute • cognitive dysfunction • continuation • melancholic • psychomotor agitation • quality of life • sleep disturbance

Journal of Psychopharmacology, Vol. 12, No. 4 suppl, S21-S54 (1998)
DOI: 10.1177/0269881198012003031


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				W. J. Riedel, K. Eikmans, A. Heldens, and J. A. J. Schmitt Specific serotonergic reuptake inhibition impairs vigilance performance acutely and after subchronic treatment J Psychopharmacol, January 1, 2005; 19(1): 12 - 20. [Abstract] [PDF]

				J. A. J. Schmitt, J. G. Ramaekers, M. J. Kruizinga, M. P. J. van Boxtel, E. F. P. M. Vuurman, and W. J. Riedel Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man J Psychopharmacol, May 1, 2002; 16(3): 207 - 214. [Abstract] [PDF]

				M. J. Millan, F. Lejeune, and A. Gobert Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents J Psychopharmacol, March 1, 2000; 14(2): 114 - 138. [Abstract] [PDF]

				P. J. Goodnick and B. J. Goldstein Selective serotonin reuptake inhibitors in affective disorders -- I. Basic pharmacology J Psychopharmacol, January 1, 1998; 12(4_suppl): 5 - S20. [Abstract] [PDF]